Completed PHASE3 INTERVENTIONAL 3-arm NCT00420212

Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis (DEFINE)

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

Sponsor: Biogen

Conditions Relapsing-Remitting Multiple Sclerosis

Interventions BG00012 Placebo

Updated 7 times since 2017 Last updated: Jan 13, 2015 Started: Jan 31, 2007 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00420212, this PHASE3 trial focuses on Relapsing-Remitting Multiple Sclerosis and remains completed. Sponsored by Biogen, it has been updated 7 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen

Data source: Biogen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Antwerp, Belgium , Ashkelon, Israel , Athens, Greece , Atlanta, United States , Bad Neustadt-Saale, Germany , Banja Luka, Bosnia and Herzegovina , Basel, Switzerland , Beer Yaakov, Israel , Belgrade, Serbia and 148 more locations